|
Diabetes Mellitus
Citations 91-100 of 340 total displayed.
|
Past content
(since Jul 1998):
|
- Commentaries
Opportunities for Enhancing the FDA Guidance on Pharmacovigilance
- Bruce M. Psaty; Jan P. Vandenbroucke
JAMA 2008; 300: 952-954.
[Extract]
[Full text]
[PDF]
- Letters
Pioglitazone vs Glimepiride in the PERISCOPE Trial
- Rahman Shah
JAMA 2008; 300: 787-a-788-a.
[Extract]
[Full text]
[PDF]
- Letters
Pioglitazone vs Glimepiride in the PERISCOPE Trial
- Claudio Fresco
JAMA 2008; 300: 787.
[Extract]
[Full text]
[PDF]
- Letters
Insulin Therapy and Lipid Overload in Type 2 Diabetes
- Paresh Dandona; Ajay Chaudhuri; Husam Ghanim
JAMA 2008; 300: 788-a-789-a.
[Extract]
[Full text]
[PDF]
- Letters
Pioglitazone vs Glimepiride in the PERISCOPE Trial—Reply
- Steven E. Nissen; Stephen J. Nicholls; Kathy Wolski
JAMA 2008; 300: 788.
[Extract]
[Full text]
[PDF]
- Letters
Insulin Therapy and Lipid Overload in Type 2 Diabetes
- Raffaele Marfella; Michelangela Barbieri; Giuseppe Paolisso
JAMA 2008; 300: 789.
[Extract]
[Full text]
[PDF]
- Letters
Insulin Therapy and Lipid Overload in Type 2 Diabetes—Reply
- Roger H. Unger
JAMA 2008; 300: 790.
[Extract]
[Full text]
[PDF]
- Preliminary Communications
Arsenic Exposure and Prevalence of Type 2 Diabetes in US Adults
- Ana Navas-Acien; Ellen K. Silbergeld; Roberto Pastor-Barriuso; Eliseo Guallar
JAMA 2008; 300: 814-822.
[Abstract]
[Full text]
[PDF]
- Editorials
Environmental Arsenic Exposure and Diabetes
- Molly L. Kile; David C. Christiani
JAMA 2008; 300: 845-846.
[Extract]
[Full text]
[PDF]
- Health Agencies Update
Drugs and Cancer Risk
- Bridget M. Kuehn
JAMA 2008; 300: 386-c.
[Extract]
[Full text]
[PDF]
|
|
